Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CARLOS E BUESO-RAMOS and SRDAN VERSTOVSEK.
CARLOS E BUESO-RAMOS
Connection Strength
3.844
SRDAN VERSTOVSEK
  1. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 May; 35(5):705.
    View in: PubMed
    Score: 0.218
  2. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 04; 35(4):470-479.
    View in: PubMed
    Score: 0.211
  3. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.208
  4. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.170
  5. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30.
    View in: PubMed
    Score: 0.160
  6. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017 09; 102(9):1511-1518.
    View in: PubMed
    Score: 0.154
  7. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.
    View in: PubMed
    Score: 0.152
  8. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma. 2017 10; 58(10):2508-2510.
    View in: PubMed
    Score: 0.152
  9. Primary autoimmune myelofibrosis: a case report and review of the literature. Int J Hematol. 2017 Apr; 105(4):536-539.
    View in: PubMed
    Score: 0.149
  10. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40.
    View in: PubMed
    Score: 0.146
  11. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
    View in: PubMed
    Score: 0.123
  12. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leuk Res. 2014 Jan; 38(1):91-4.
    View in: PubMed
    Score: 0.121
  13. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.
    View in: PubMed
    Score: 0.115
  14. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552.
    View in: PubMed
    Score: 0.114
  15. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010 Jan 15; 70(2):447-52.
    View in: PubMed
    Score: 0.093
  16. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.
    View in: PubMed
    Score: 0.087
  17. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.
    View in: PubMed
    Score: 0.083
  18. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008 Jun; 22(6):1295-8.
    View in: PubMed
    Score: 0.080
  19. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
    View in: PubMed
    Score: 0.057
  20. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.055
  21. Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. Br J Haematol. 2022 08; 198(3):604-608.
    View in: PubMed
    Score: 0.055
  22. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.051
  23. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.051
  24. Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution. Cytometry B Clin Cytom. 2021 05; 100(3):352-360.
    View in: PubMed
    Score: 0.047
  25. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One. 2019; 14(9):e0222912.
    View in: PubMed
    Score: 0.046
  26. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
    View in: PubMed
    Score: 0.042
  27. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.042
  28. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.041
  29. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.041
  30. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018 03 15; 11(1):42.
    View in: PubMed
    Score: 0.041
  31. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018 Mar; 97(3):425-434.
    View in: PubMed
    Score: 0.040
  32. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.040
  33. Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw. 2017 06; 15(6):790-796.
    View in: PubMed
    Score: 0.039
  34. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
    View in: PubMed
    Score: 0.039
  35. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
    View in: PubMed
    Score: 0.038
  36. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
    View in: PubMed
    Score: 0.037
  37. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.037
  38. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 08; 29(8):854-64.
    View in: PubMed
    Score: 0.036
  39. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27.
    View in: PubMed
    Score: 0.036
  40. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
    View in: PubMed
    Score: 0.031
  41. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol. 2013 Oct; 91(4):378-9.
    View in: PubMed
    Score: 0.030
  42. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):629-33.
    View in: PubMed
    Score: 0.030
  43. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013 Oct; 92(10):1335-43.
    View in: PubMed
    Score: 0.029
  44. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013 Mar; 88(3):219-24.
    View in: PubMed
    Score: 0.029
  45. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6.
    View in: PubMed
    Score: 0.025
  46. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
    View in: PubMed
    Score: 0.024
  47. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9.
    View in: PubMed
    Score: 0.023
  48. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.023
  49. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63.
    View in: PubMed
    Score: 0.022
  50. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009 Jan; 22(1):50-7.
    View in: PubMed
    Score: 0.021
  51. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia. 2007 Jul; 21(7):1574-6.
    View in: PubMed
    Score: 0.019
  52. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
    View in: PubMed
    Score: 0.018
  53. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
    View in: PubMed
    Score: 0.018
  54. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
    View in: PubMed
    Score: 0.017
  55. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
    View in: PubMed
    Score: 0.017
  56. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005 Nov 15; 106(10):3370-3.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.